Lonza Launches Next Generation 4D-Nucleofector LV Unit PRO For Improved Electroporation In GMP Manufacturing

• Launch enables efficient and scalable electroporation across research applications up to GMP manufacturing
• New system includes optimized cartridge design for improved performance for CRISPR-based knock-out, knock-in and transposition

Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of 4D-Nucleofector LV Unit PRO, their next-generation large-scale electroporation unit designed to deliver clinically relevant cargos into large volumes of T cells. This unit builds on Lonza’s well-established non-viral large-scale transfection platform and is optimized for CRISPR-based genome engineering and other advanced cell therapy applications.

For more than twenty years, Lonza’s Nucleofector Technology has been a cornerstone in cell and gene therapy R&D, enabling efficient delivery into hard-to-transfect primary cells, such as T cells. The newly introduced 4D-Nucleofector LV Unit PRO further advances this technology, offering enhanced performance for CRISPR-based knock-out, knock-in and transposition.

A key innovation is the implementation of the new Nucleocuvette Cartridges PRO, an improved cartridge version that enables the electroporation of complex cargos into up to one billion cells per run. The new cartridge supports complex clinically-relevant cargo delivery and introduces several usability improvements, including greater flexibility, simplified loading and clearing, and increased robustness of the flow-through process. The upgraded system is suited for preclinical studies and process development, serving as a scalable and reproducible platform for a seamless translation from discovery projects to GMP-compliant manufacturing for next-generation cell and gene therapies.

Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza, said: “Lonza’s large-scale 4D-Nucleofector LV Unit has been pivotal in supporting non-viral manufacturing of advanced therapy medicinal products. With the launch of the next-generation 4D-Nucleofector LV Unit PRO, we are extending these capabilities to support GMP manufacturing across scales, enabling smoother process development and a seamless translation from R&D to clinical manufacture.”

Additional Information

For more information, visit https://bioscience.lonza.com/

For more information, visit https://bioscience.lonza.com/large-scale-electroporation